Plasma proteomic biomarker signature of age predicts health and life span

  1. Toshiko Tanaka  Is a corresponding author
  2. Nathan Basisty
  3. Giovanna Fantoni
  4. Julian Candia
  5. Ann Z Moore
  6. Angelique Bioancotto
  7. Birgit Schilling
  8. Stefania Bandinelli
  9. Luigi Ferrucci
  1. National Institute on Aging, NIH, United States
  2. Buck Institute for Research on Aging, United States
  3. National Cancer Institute, NIH, United States
  4. Sanofi, United States
  5. Azienda Sanitaria di Firenze, Italy

Abstract

Older age is a strong shared risk factor for many chronic diseases and there is increasing interest in identifying aging biomarkers. Here a proteomic analysis of 1301 plasma proteins was conducted in 997 individuals between 21 and 102 years of age. We identified 651 proteins associated with age (506 over-represented, 145 underrepresented with age) was identified. Mediation analysis suggested a role for partial cis-epigenetic control of protein expression with age. Of the age-associated proteins, 33.5% and 45.3%, were associated with mortality and multimorbidity, respectively. There was enrichment of proteins associated with inflammation and extracellular matrix as well as senescence-associated secretory proteins. A 76-protein proteomic age signature predicted accumulation of chronic diseases and all-cause mortality. These data support the premise of proteomic biomarkers to monitor aging trajectories and to identify individuals at higher risk for disease to be targeted for in depth diagnostic procedures and early interventions.

Data availability

Phenotypic data and source codes used for this manuscript is provided. Due to the contents of the InCHIANTI study consent forms, proteomic and DNA methylation data cannot be made publicly available. Researchers can seek access to these data through the submission of proposals and subsequent approval through the InCHIANTI study website (inchiantistudy.net).

Article and author information

Author details

  1. Toshiko Tanaka

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    For correspondence
    tanakato@mail.nih.gov
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4161-3829
  2. Nathan Basisty

    Buck Institute for Research on Aging, Novato, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Giovanna Fantoni

    Clinical Research Core, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Julian Candia

    Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5793-8989
  5. Ann Z Moore

    Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Angelique Bioancotto

    Immunology & Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Birgit Schilling

    Buck Institute for Research on Aging, Novato, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9907-2749
  8. Stefania Bandinelli

    Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy
    Competing interests
    The authors declare that no competing interests exist.
  9. Luigi Ferrucci

    Intramural Research Program, National Institute on Aging, NIH, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6273-1613

Funding

National Institutes of Health (U01 AG060906)

  • Birgit Schilling

National Institutes of Health (K99 AG065484)

  • Nathan Basisty

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study protocol (exemption #11976) was approved by the Italian National Institute of Research and Care of Aging Institutional Review and Medstar Research Institute (Baltimore, MD) and approved by the Internal Review Board of the National Institute for Environmental Health Sciences (NIEHS).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 9,376
    views
  • 1,194
    downloads
  • 105
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Toshiko Tanaka
  2. Nathan Basisty
  3. Giovanna Fantoni
  4. Julian Candia
  5. Ann Z Moore
  6. Angelique Bioancotto
  7. Birgit Schilling
  8. Stefania Bandinelli
  9. Luigi Ferrucci
(2020)
Plasma proteomic biomarker signature of age predicts health and life span
eLife 9:e61073.
https://doi.org/10.7554/eLife.61073

Share this article

https://doi.org/10.7554/eLife.61073

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.

    1. Computational and Systems Biology
    David B Blumenthal, Marta Lucchetta ... Martin H Schaefer
    Research Article Updated

    Degree distributions in protein-protein interaction (PPI) networks are believed to follow a power law (PL). However, technical and study biases affect the experimental procedures for detecting PPIs. For instance, cancer-associated proteins have received disproportional attention. Moreover, bait proteins in large-scale experiments tend to have many false-positive interaction partners. Studying the degree distributions of thousands of PPI networks of controlled provenance, we address the question if PL distributions in observed PPI networks could be explained by these biases alone. Our findings are supported by mathematical models and extensive simulations, and indicate that study bias and technical bias suffice to produce the observed PL distribution. It is, hence, problematic to derive hypotheses about the topology of the true biological interactome from the PL distributions in observed PPI networks. Our study casts doubt on the use of the PL property of biological networks as a modeling assumption or quality criterion in network biology.